The Centers for Medicare & Medicaid Services (CMS) has added 22 HCPCS codes in nine durable medical equipment (DME) ...
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before ...
The amount Medicare pays per RVU gets its first substantial boost in years, but most of the increase will expire at the end of 2026 unless Congress acts. Editor's note: This article was updated to ...
ISELIN - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...
Outlook Therapeutics, Inc. announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure ...
Outlook Therapeutics, Inc. a annoncé avoir soumis aux Centers for Medicare & Medicaid Services une demande visant à obtenir un code J permanent, spécifique au produit, dans le cadre du ...
Outlook Therapeutics, Inc. hat bekannt gegeben, bei den Centers for Medicare & Medicaid Services einen Antrag auf Erteilung eines dauerhaften, produktspezifischen J-Codes der Stufe II des Healthcare..
Lantheus Holdings, Inc. gab bekannt, dass die Centers for Medicare & Medicaid Services PYLARIFY® TruVu™ Injektionslösung mit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results